According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- BMN 307, an AAV5 mediated gene therapy, was less safe than BioMarin had led investors to believe;
- BMN 307’s safety profile made it likely that the U.S. Food and Drug Administration (FDA) would place a clinical hold on the Phearless Phase 1/2 study;
- accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
